Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, iBio Inc (NASDAQ: IBIO) closed at $0.73 down -1.33% from its previous closing price of $0.74. In other words, the price has decreased by -$1.33 from its previous closing price. On the day, 1.8 million shares were traded. IBIO stock price reached its highest trading level at $0.7799 during the session, while it also had its lowest trading level at $0.67.
Ratios:
For a deeper understanding of iBio Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.12 and its Current Ratio is at 1.12. In the meantime, Its Debt-to-Equity ratio is 0.34 whereas as Long-Term Debt/Eq ratio is at 0.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Chardan Capital Markets on May 28, 2024, initiated with a Buy rating and assigned the stock a target price of $5.
On November 29, 2021, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $1.50.
On January 22, 2021, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $3.Cantor Fitzgerald initiated its Overweight rating on January 22, 2021, with a $3 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 10 ’25 when Duran Felipe bought 9,191 shares for $2.72 per share. The transaction valued at 25,000 led to the insider holds 11,139 shares of the business.
Brenner Martin bought 9,191 shares of IBIO for $25,000 on Jan 10 ’25. The insider now owns 18,316 shares after completing the transaction at $2.72 per share. On Jan 10 ’25, another insider, Banjak Marc, who serves as the Chief Legal Officer of the company, bought 9,191 shares for $2.72 each. As a result, the insider paid 25,000 and bolstered with 11,066 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IBIO now has a Market Capitalization of 11887125 and an Enterprise Value of 11631522. For the stock, the TTM Price-to-Sale (P/S) ratio is 31.29 while its Price-to-Book (P/B) ratio in mrq is 0.65. Its current Enterprise Value per Revenue stands at 31.017 whereas that against EBITDA is -0.726.
Stock Price History:
The Beta on a monthly basis for IBIO is 0.85, which has changed by -0.6456311 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, IBIO has reached a high of $6.89, while it has fallen to a 52-week low of $0.56. The 50-Day Moving Average of the stock is -2.31%, while the 200-Day Moving Average is calculated to be -66.18%.
Shares Statistics:
For the past three months, IBIO has traded an average of 2.11M shares per day and 1000000 over the past ten days. A total of 16.22M shares are outstanding, with a floating share count of 15.31M. Insiders hold about 5.61% of the company’s shares, while institutions hold 19.75% stake in the company. Shares short for IBIO as of 1753920000 were 553594 with a Short Ratio of 0.26, compared to 1751241600 on 2250783. Therefore, it implies a Short% of Shares Outstanding of 553594 and a Short% of Float of 3.42.
Earnings Estimates
Its stock is currently analyzed by 2.0 different market analysts. The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.2 and low estimates of -$0.2.
Analysts are recommending an EPS of between -$1.77 and -$1.77 for the fiscal current year, implying an average EPS of -$1.77. EPS for the following year is -$0.76, with 2.0 analysts recommending between -$0.7 and -$0.82.
Revenue Estimates
A total of 2 analysts have provided revenue estimates for IBIO’s current fiscal year. The highest revenue estimate was $600k, while the lowest revenue estimate was $200k, resulting in an average revenue estimate of $400k. In the same quarter a year ago, actual revenue was $225k
